Search
You're invited to try out the new version of Value Research Online. Click here to begin: https://beta.valueresearchonline.com

Ind-Swift Laboratories

Sector: Healthcare | Industry: Drugs & Pharma
R 31.95 -0.15  | -0.47% -45.80% 35.91 150.08
NSE Price: Oct 22, 15:53 Change R    |  % 1-Year Change P/E Market Cap (R Cr)
NSE Oct 22, 15:53 31.95 -0.15 -0.47% 32.05 32.10 25,036 30.50 - 33.40
BSE Oct 22, 2019 31.55 -1.60 -4.83% 34.60 33.15 5,409 31.50 - 34.60
Exchange & Time Last Price      Day Change Open Prev Close Volume    1-Day Range
SUBSCRIBE TO THE FREE VALUE RESEARCH STOCK INSIGHT NEWSLETTER
6M Average Volume: 141,982 P/B: 0.43 NSE Code: INDSWFTLAB
52-Week Range: R 30.05 - 64.25 Dividend Yield: 0.00% BSE Code: 532305
TTM EPS: R 0.88 Book Value: R 72.96 Face Value: R 10
Number of stocks currently recommended as 'Buy' by Value Research Stock Advisor: 38
Price Graph
  • Eris Lifesciences (NSE)
  • S&P BSE Sensex


Please wait while we are fetching data...
Our equity analyst team has sifted through hundreds of companies and selected a short list of stocks that you should invest in.
This list now has 38 stocks on it. Thousands of our members are using stagnant equity markets to buy great stocks at low prices.

Membership is currently available at a 40% to 60% discount. Learn more and become a member
Performance
  YTD 1-Month 3-Month 1-Year 3-Year 5-Year 10-Year
Ind-Swift Laboratories -34.33 -29.39 -0.93 -45.80 -8.89 -0.16 -7.39
S&P BSE Small Cap -10.31 -0.11 0.26 -4.45 -0.60 4.66 5.60
S&P BSE Healthcare -7.84 -1.42 0.06 -11.61 -7.74 -1.50 11.51
Company's return has been calculated on basis of NSE's price.
As on Oct 22, 2019
Key Ratios
Revenue Per Share (R) Earnings Per Share (R) Return on Networth (%)


Please wait
while we are fetching data...


Please wait
while we are fetching data...


Please wait
while we are fetching data...
Annual Ratios (%)
  1-Year 3-Years 5-Years
Growth
Revenue -0.78 5.02 -4.75
Net Profit 74.92 38.47 18.28
EPS 67.24 36.91 17.84
Book Value 17.01 10.56 -3.79
Average
Operating Margin 22.79 20.73 19.57
Net Margin 4.85 0.73 -4.81
Return on Networth 11.64 1.21 -11.17
Return on Investment 9.72 5.50 3.28
Interim Growth Ratios (%)
  QoQ YoY YTD
Quarterly
Revenue -5.71 1.34 -5.71
Operating Profit -35.28 0.10 -35.28
Net Profit 29.55 -159.57 29.55
EPS 29.55 -156.70 29.55
TTM
Revenue 0.33 -2.57 0.33
Operating Profit 0.02 -7.54 0.02
Net Profit -91.31 -93.86 -91.31
EPS -91.55 -94.16 -91.55
Peer Comparison
  Market Cap
(R Cr)
Revenue
(R Cr)
Net Profit
(R Cr)
Net Margin (%) RoE (%) Price to Book Price to Earnings
Ind-Swift Laboratories 150.08 726.81 4.18 0.55 11.64 0.43 35.91
Astrazeneca Pharma India 6,030.25 771.42 69.56 8.84 20.03 18.83 86.69
Eris Lifesciences 5,850.09 1,005.70 303.64 29.29 28.96 4.74 19.27
Insider Trades
Date Person  Buy / Sell Transaction
Type
No of Shares Price
(R)   
Value
(R Lakhs)
Jul 25, 2018 Edelweiss India Special Situations Fund-II  Buy Preferential Allotment 11,517,670 80.15 9,231.41
Dec 09, 2017 Essix Biosciences LTD  Buy Scheme Of Amalgamation 7,335,986 38.80 2,846.36
Dec 08, 2017 AKJ PORTFOLIOS PVT LTD  Sell Scheme Of Amalgamation 2,025,573 38.80 785.92
Dec 08, 2017 GM PORTFOLIOS PRIVATE LIMITE  Sell Scheme Of Amalgamation 735,900 38.80 285.53
Dec 08, 2017 N R M PORTFOLIOS PVT LTD  Sell Scheme Of Amalgamation 1,743,294 38.80 676.40
Fund Houses invested in the stock
Fund Dec-12 Sep-12 Jun-12 Mar-12 Dec-11
Goldman Sachs Mutual Fund 0.001 0.001 - 0.002 -
Figures given above are % of equity capital
Review & Analysis
News & Announcements
Contact Information

Company: Ind-Swift Laboratories Ltd.

Address: S C O 850, Shivalik Enclave, N A C, Manimajra, Chandigarh, Punjab - 160101 | Phone: 172-2730503/2730920/5061850/51/52/53 | Fax: 172-2730504

Email: [email protected]

Website: www.indswiftlabs.com

Registrar & Transfer Agent: Alankit Assignments Ltd

Address: 205-208 , Anarkali Complex,Jhandewala Extension,New Delhi, 205-208 , Anarkali Complex, Jhandewala Extension | Phone: 011-23610220-24 | Fax: 011-23552001

Essential checks
Altman Z-Score
1.39
Piotroski F-Score
6
Modified C-Score
1
5-Years Price to Earnings
35.91
5-Years Price to Book
0.43
Earnings Yield
EBIT / Enterprise value
10.30%
PEG
Price / Earnings to growth ratio
2.36
Related Stocks
  Current Price   Chng %
Astrazeneca Pharma India R2,412.00 +5.87%
Caplin Point Laboratories R387.75 -2.29%
Eris Lifesciences R425.40 +0.66%
FDC R160.95 +0.03%
JB Chemicals & Pharma R359.80 -1.84%
Laurus Labs R341.70 +8.06%
Strides Pharma Science R350.75 -0.88%
Sun Pharma Adv. Research R132.60 +0.08%
Suven Life Sciences R286.65 +2.17%
Wockhardt R275.20 +3.28%
As on Oct 22, 15:59